Scholarlink

<p>Cellular based therapies, such as bispecific T-cell engagers (TCE), have changed the landscape of myeloma treatment, but to the present day little is known about the use of these therapies in patients with prior allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this case report, we present a patient with multi-refractory multiple myeloma (MM), who relapsed after allo-HSCT and anti-SLAMF-7-CART-cell-therapy and was ultimately successfully treated with teclistamab, a BCMA-directed TCE, and we discuss theoretical considerations based on present literature about possible underlying immunological mechanisms, that might have contributed to a long enduring treatment response.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long enduring response on teclistamab in a patient with myeloma relapse after allogeneic hematopoietic stem cell transplantation – a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月7日

查看全文
  • P. Ebner,
  • J. Fauser,
  • G. Hetzenauer,
  • S. Köck,
  • W. Willenbacher,
  • L. M. Rossetti,
  • T. A. Buchwald,
  • L. Rasche,
  • E. Gunsilius,
  • D. Nachbaur,
  • D. Wolf,
  • N. Steiner

摘要

Cellular based therapies, such as bispecific T-cell engagers (TCE), have changed the landscape of myeloma treatment, but to the present day little is known about the use of these therapies in patients with prior allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this case report, we present a patient with multi-refractory multiple myeloma (MM), who relapsed after allo-HSCT and anti-SLAMF-7-CART-cell-therapy and was ultimately successfully treated with teclistamab, a BCMA-directed TCE, and we discuss theoretical considerations based on present literature about possible underlying immunological mechanisms, that might have contributed to a long enduring treatment response.